[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:immunodeficiency-13":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":22,"states":23},"IMMUNODEFICIENCY 13",2,[7,15],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05600920","A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:00.194860Z","2026-05-05T02:43:26.977893Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04097561","Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)",[19],"Phase 1","2026-08-26T02:18:40.612983Z","2026-05-05T02:35:31.916745Z",[],[]]